Please login to the form below

Not currently logged in
Email:
Password:

Trial success for MSD's HIV drug

MSD's Isentress has demonstrated efficacy regardless of gender or race in a diverse population of adult patients with HIV-1 infection in an observational phase III study

MSD's Isentress (raltegravir) has demonstrated efficacy and tolerability when used as part of combination therapy regardless of gender or race in a diverse population of adult patients with HIV-1 infection in an observational phase III study.

The REALMRK study enrolled a total of 209 patients, 156 of whom were black and 98 of whom were female, with data obtained compared to previous phase III studies involving Isentress.

All participants were adult HIV-1-infected patients who had not undergone treatment previously, or were failing or intolerant to current antiretroviral (ARV) treatment.

Lead investigator Dr Kathleen Squires, director of the division of infectious disease and environmental medicine, Jefferson Medical College of Thomas Jefferson University, and the study demonstrated the benefits of the drug in the diverse patient populations affected by HIV today, pointing out that black populations and women are disproportionately affected by the HIV epidemic.

MSD is known as Merck in the US and Canada.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics